Earnings ·
Sanofi reported Q2 2026 net sales of €11,597 million, a 17.8% increase at constant exchange rates (CER), driven by a…
SNYNFSanofi
Sanofi reported Q2 2026 net sales of €11,597 million, a 17.8% increase at constant exchange rates (CER), driven by a 48.3% surge in Pharma launches to €1.3 billion and Dupixent sales rising 37.6% to €5.2 billion. Business EPS grew 33.3% at CER to €2.09, while IFRS EPS was €0.29 due to non-cash amortization and impairment charges totaling over €2 billion. The company upgraded its full-year 2026 guidance, now expecting sales growth of around 10% at CER with business EPS growing slightly faster than sales. Pipeline updates included seven regulatory approvals, two positive Phase 3 readouts for Nexviazyme and amlitelimab, and the discontinuation of development programs for amlitelimab, itepekimab, and balinatunfib. Sanofi operates in the pharmaceutical industry.